Objective. To determine whether the aminopeptidase B inhibitor, arphamenine A, could affect collagen production and expression in control and TGF-ß1-treated cardiac fibroblasts.
Design and Methods. Cardiac fibroblasts from passage 2 from normal male adult rats were cultured to confluency and incubated with and without 600 pmol/l TGF-ß1 for 2 days in serum-free Dulbecco's modified Eagle's medium and then incubated with 100 µmol/l arphamenine A for 1 day in this medium added ascorbic acid, ß-aminopropionitrile and titriated proline. Soluble collagen was measured in the conditioned medium and non-soluble collagen in the cell layer. Aminopeptidase activity was estimated by spectrophotometric determination of the liberation of p-nitroaniline from alanine- or arginine-p-nitroanilide. Matrix metalloproteinase (MMP) and lysyl oxidase activity were assayed in the conditioned medium. A semi-quantitative reverse transcriptase- polymerase chain reaction was used to examine the expression of lysyl oxidase and collagen type I and III. Results. Arphamenine A dose-dependently
inhibited basal and TGF-ß 1-stimulated aminopeptidase activity. Arphamenine A reduced soluble and non-soluble collagen production in control and TGF-ß1-treated cardiac fibroblasts, while it decreased collagen type I and III expression only in TGF-ß1-treated fibroblasts. Lysyl oxidase, MMP-1 and MMP-2 activity were inhibited by arphamenine A in the conditioned media of control and TGF-ß1treated cardiac fibroblasts.
Conclusions. Our data show that the specific aminopeptidase B inhibitor, arphamenine A, reduces collagen production in cardiac fibroblasts and that this reduction is accompanied by a pronounced inhibition of lysyl oxidase.
Petrov V., Fagard R., Lijnen P.Transforming growth factorbeta1 induces angiotensin converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts . JRAAS2000;1:342-52.
2.
Petrov V., Fagard R., Lijnen P.Stimulation of collagen production by transforming growth factor-ß1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension2002;39:258-63.
3.
Lijnen P., Petrov V., Fagard R.Transforming growth factor ß1-mediated collagen gel contraction by cardiac fibroblasts. JRAAS2003;4:113-18.
4.
Petrov V., Fagard R., Lijnen P.Induction of various aminopeptidases in cardiac fibroblasts by transforming growth factor-beta1. J Hypertension2003;21:S239.
5.
Petrov V., Fagard R., Lijnen P.Arginine-aminopeptidase in rat cardiac fibroblastic cells participates in angiotensin peptide turnover. Cardiovasc Res2004;61:724-35.
6.
Lijnen P., Fagard R., Lijnen P.Collagen production in cardiac fibroblasts during inhibition of angiotensin converting enzyme and aminopeptidases. J Hypertension2004;22:209-16.
7.
Lijnen P., Petrov V., Fagard R.Reversal of angiotensin II-stimulated collagen gel contraction in cardiac fibroblasts by aminopeptidase-inhibition. Am J Cardiovasc Pharmacol2005;45:68-73.
8.
Lijnen P., Petrov V., Fagard R.Effect of bestatin on angiotensin I-, II- and III-induced stimulation of collagen gel contraction in cardiac fibroblasts. JRAAS2004;5:183-8.
9.
Brilla CG, Zhou G., Matsubara L., Weber KTCollagen metabolism in cultured adult rat cardiac fibroblasts. Respone to angiotensin II and aldosterone. J Mol Cell Cardiol1994;26:809-20.
10.
De Young MB, Giannattasio B., Scarpa A.Isolation of calcium-tolerant atrial and ventricular myocytes from adult rat heart. In: Biomembranes, Fleischer S & Fleischer B, eds, Academic Press, 1989; pp. 662-76.
11.
Peterkofski B.Estimation of total collagen production by collagenase digestion. In: Extracellular Matrix, Haralson MA & Hassell JR, eds., Oxford University Press, 1995; pp. 31-8.
12.
Köhler E., Bertschin S., Woodtli T., Resink T., Erne P.Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts?J Vasc Res1996;33:315-26.
13.
Downs TR, Wilfinger WWFluorimetric quantification of DNA in cells and tissue. Anal Biochem1983;131:538-47.
14.
Palamakumbura AH, Trackman PCA fluorimetric assay for detection of lysyl oxidase enzyme activity in biological samples. Anal Biochem2002;300:245-51.
15.
Chirgwin JM , Przybyla AE, MacDonald RJ, Rutter WJIsolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry1979;18:5294-9.
16.
Chomzynski P., Sacchi N.Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem1987;162:156-7.
17.
Nakagawa S. , Pawelek P., Grinell F.Extracellular matrix organization modulates growth and growth factor responsiveness. Exper Cell Res1989;182:572-82.
18.
Kagan HM, Li W.Lysyl oxidase: Properties, specificity and biological role inside and outside the cell. J Cell Biochem2003;88:660-72.
19.
Smith-Mungo L., Kagan H., Lysyl oxidase: Properties, regulation and multiple function in biology. Matrix Biol1998;16:387-98.
20.
Kagan HMCharacterization and regulation of lysyl oxidase. In "Biology of extracellular matrix: A Series. Regulation of matrix accumulation" Vol. 1RP Mecham, ed., Acad. Press, Orlando, 1986, pp. 321-98.
21.
Tsuda T., Gao E., Evangelista L., Markova D., Ma X., Chu MLPost-ischemic myocardial fibrosis occurs independent of hemodynamic changes . Cardiovasc Res2003;59:926-33.
22.
McCormick RJ , Musch TJ, Bergman BC, Thomas DP, Regional differences in LV collagen accumulation and mature cross-linking after myocardial infarction in rats. Am J Physiol1994;266:H354-9.
23.
Kato S., Spinale R., Tanaka R., Johnson W., Cooper G., Zile MRInhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol1995;269:H863-8.
24.
Norton GR, Tsotetsi J., Trifunovic B., Hartford C., Candy GP, Woodiwiss AJMyocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats . Circulation1997;96: 1991-8.
25.
Badenhorst D., Maseko M., Tsotetsi OJ et al. Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodeling in hypertension in rats. Cardiovasc Res2003 ;57:632-41.
26.
Koshy SKG , Reddy HK, Shukla HHCollagen cross-linking: a new dimension to cardiac remodeling. Cardiovasc Res2003;57:594-8.
27.
Woodiwiss AJ , Tsotetsi OJ, Sprott S. et al. Reduction in myocardial collagen cross-linking parallels ventricular dilatation in rat models of systolic chamber dysfunction . Circulation2001;103:155-60.
28.
Strauss BH, Robinson R., Batchelor WB et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res1996;79:541-50.
29.
Strauss BH, Chisholm RJ, Keeley FW, Gotlieb AI, Logan RA, Armstrong PWExtracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res1994 ;75:650-8.
30.
Sluijter JPG , Smeets MB, Velema E., Pasterkamp G., de Kleijn DPV.Increased collagen turnover is only partly associated with collagen fiber deposition in the arterial response to injury . Cardiovasc Res2004;61:186-95.
31.
Spinale FGMatrix metalloproteinases. Regulation and dysregulation in the failing heart . Circ Res2002;90:520-30.
32.
Tyagi SC, Kumar SG, Alla SR, Reddy HK, Voelker DJ, Janicki JSExtracellular matrix regulation of metalloproteinase and antiproteinase in human heart fibroblasts. J Cell Physiol1996 ;167:137-47.
33.
Tyagi SC, Campbell SE, Reddy HK, Tjahja E., Voelker DJMatrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem1996;155:13-21.
Capasso JM, Robinson TF, Anversa P.Alterations in collagen cross-linking impair myocardial contractility in the mouse heart. Circ Res1989;65:1657-64.
36.
Gunja-Smith Z., Morales AR, Romanelli R., Woessner J. Jr.Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinasess and pyridinoline cross-links. J Pathol1996;148:1639-48.
37.
Spinale FG, Zellner JL, Johnson WS, Eble DM, Munyer PLCellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol1996;28:1591-608.
38.
Burgess ML, Carver WE, Terracio L., Wilson SP, Borg TKIntegrin-mediated collagen gel contraction by cardiac fibroblasts . Circ Res1994;74:291-8.
39.
Watson S., Burnside T., Carver W.Angiotensin II-stimulated collagen gel contraction hy heart fibroblasts. Role of the AT1-receptor and tyrosine kinase activity. J Cell Physiol1998;177: 224-31.
40.
Aoyagi T., Wada T., Kojima F. et al. Inhibitors of aminopeptidase B suppress the development of hypertension in spontaneously hypertensive rats. Chem Pharm Biol1986;34:4852-4.
41.
Kitamura S. , Carbini LA, Simmons WH, Scicli AGEffects of aminopeptidase P inhibition on kinin-mediated vasopressor responses. Am J Physiol1999;276:H1664-71.
42.
Dzoljic E., Varagic VMEffects of bestatin and phosphoramidon on the hypertensive response to physostigmine in the rat. Fundam Clin Pharmacol1987;1:307-16.
43.
Jensen LL, Harding JW, Wright JWIncreased blood pressure induced by central application of aminopeptidase inhibitors is angiotensinergic-dependent in normotensive and hypertensive rat strains. Brain Res1989;490:48-53.
44.
Reaux HA, Fournie-Zaluski MC, David C. et al. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci USA1999;96:13415-20.
